Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Chemotherapy Market to Hit $20.99 Billion by 2035, Driven by Rising Cancer Incidence – SNS Insider

globenewswire.com
NVS Novartis continues commercialization of its radioligand therapy Pluvicto, increasing patient access to novel cancer treatments. This expansion suggests positive market engagement and potential for increased revenue. PFE Pfizer secured FDA approval for BRAFTOVI in combination with chemotherapy for metastatic colorectal cancer. This approval solidifies its position in cancer treatment and indicates potential for increased sales.

Chemotherapy Market to Hit $20.99 Billion by 2035, Driven by Rising Cancer Incidence – SNS Insider Austin, United States, March 30, 2026 (GLOBE NEWSWIRE) -- Chemotherapy Market Size & Growth Analysis:

According to SNS Insider, the Chemotherapy Market was valued at $10.14 billion in 2025, which is expected to grow to $20.99 billion by 2035, with a CAGR of 7.57% from 2026 to 2035. The Chemotherapy Market is growing steadily due to the increasing incidence of cancer worldwide, in combination with the constant development of new drugs for chemotherapy.

The increasing use of chemotherapy as a basis for cancer treatment continues to fuel market growth, with 10 billion treatment doses of chemotherapy used worldwide in 2025. The increasing use of chemotherapy in combination with other treatments, such as targeted therapies and immunotherapies, continues to improve treatment outcomes for patients.

Get a Sample Report of Chemotherapy Market: https://www.snsinsider.com/sample-request/9890

The U.S. Chemotherapy Market is estimated at $3.52 billion in 2025 and is projected to reach $6.93 billion in 2035, growing at a CAGR of 7.02% during the forecast period. The United States is at the forefront of the global chemotherapy market due to its developed infrastructure, presence of prominent oncology centers, and high rate of adoption of innovative cancer treatments.

The United States is also benefiting from high investment in oncology research, favorable reimbursement rates, and high availability of innovative treatments, which is further enhancing its stronghold in the global chemotherapy market.

Rising Cancer Incidence Drives Market Demand

The growing global cancer burden is still the key driver of the chemotherapy market. With millions of new cancer patients being diagnosed worldwide, chemotherapy is still playing an important role in both early-stage and advanced-stage cancer treatment. The growing trend of using advanced oncology treatments is also contributing to the growth of the chemotherapy market.

Chemotherapy is still being used for treating various types of cancer, including lung cancer, breast cancer, colorectal cancer, and blood cancer. Its effectiveness in tumor shrinkage, metastasis, and survival rates makes chemotherapy an essential part of cancer treatment.

Side Effects and High Costs Pose Market Challenges

Despite its strong growth prospects, the chemotherapy market is also facing certain challenges. These challenges include severe side effects and the cost of treatment. Adverse effects of chemotherapy include nausea, fatigue, immunosuppression, and other complications.

The cost of chemotherapy is another factor hindering its adoption. Chemotherapy is expensive, and its cost is affecting developing countries. These are some of the challenges affecting the chemotherapy market. Despite its strong growth prospects, these challenges are hindering its adoption. In some countries, advanced healthcare facilities are not readily available.

Chemotherapy Market Segmentation Analysis:

By Drug Type

Antimetabolites accounted for the highest market share of 28.45% in 2025 due to its wide scope of applications in treating various types of cancer. On the other hand, topoisomerase inhibitors are expected to witness the highest CAGR of 8.92% during 2026-2035 due to its rising adoption in target-based treatment schemes.

By Route of Administration

The intravenous segment held the largest share in the market in 2025, accounting for 61.37%, due to its efficient delivery of drugs into the bloodstream. The oral segment is expected to show the highest CAGR of 9.14%, driven by the preference of patients for home-based treatments.

By Cancer Indication

Lung cancer had the highest market share of 24.18% in 2025 due to its higher prevalence and preference for chemotherapy as a primary method of treatment. Blood cancer is expected to record the highest CAGR of 8.76% due to increased incidence rates and better therapeutic options for blood cancer.

By Distribution Channel

Hospital pharmacies had the highest market share of 57.21% in 2025, as chemotherapy administration occurs primarily in clinical settings. Online pharmacies are expected to grow the fastest, achieving a CAGR of 10.12%, as digital healthcare and drug accessibility are becoming more prevalent.

By End User

Hospitals & Clinics held the largest market share of 52.63% in 2025 due to their better infrastructure, which can handle complex chemotherapy procedures. The home care segment is expected to register the highest CAGR of 9.38% due to the increasing use of home infusion therapies.

Need Any Customization Research on Chemotherapy Market, Enquire Now: https://www.snsinsider.com/enquiry/9890

Chemotherapy Market Regional Insights:

North America led the chemotherapy market in 2025, with a revenue share of 41.26%. This is because of the high incidence rate of cancer in the region, which is accompanied by the presence of good healthcare infrastructure and easy access to latest treatments in cancer management.

The Asia-Pacific market is the fastest-growing market, with a CAGR of 9.36% during the forecast period. The growth of the market in the Asia-Pacific region is due to the increasing prevalence of cancer, better healthcare facilities, and increasing investments in oncology care in countries such as China and India. Moreover, increasing awareness about the importance of early diagnosis and treatment is also contributing to the growth of the market for chemotherapy.

Recent Developments:

In January 2025, F. Hoffmann-La Roche Ltd. secured approval for its inavolisib under the brand name Itovebi for advanced breast cancer, further enhancing its presence in cancer treatment with chemotherapy combinations.

In November 2025, Novartis AG continued its commercialization of its radioligand therapy Pluvicto, increasing patient access to novel cancer treatments.

In February 2026, Pfizer Inc. secured FDA approval for its BRAFTOVI in combination with chemotherapy for treating metastatic colorectal cancer, further solidifying its position in cancer treatment.

Major Chemotherapy Companies Analysis Listed in the Report are:

Chemotherapy Market Segmentation:

By Drug Type

By Route of Administration

By Cancer Indication

By End User

By Distribution Channel

Purchase Single User PDF of Chemotherapy Market Report (20% Discount): https://www.snsinsider.com/checkout/9890

Exclusive Sections of the Report (The USPs):

Browse More Reports:

Oncology Drugs Market

Compounding Chemotherapy Market

Immunotherapy Drugs Market

Radiotherapy Market

Cancer Diagnostics Market

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.